3/4 #KidneyCancer at #ESMO26 🟠 #LITESPARK011 — 3587O, 3595RO - Belzutifan + lenvatinib improved PFS vs cabo after IO (14.8 vs 10.7 mo; HR 0.70), leading to September FDA approval. Final OS not significant (HR 0.85). - ESMO adds detailed final and QoL analyses. Looking at prior-treatment subgroups and how benefit balances anemia/hypoxia and TKI toxicity. 🟣 #LITESPARK012 — 3586O - Adding belzutifan to frontline pembro/len missed PFS/OS endpoints. Full results should clarify efficacy and treatment delivery. - Better disease control after IO, but unsuccessful frontline intensification. Where does HIF-2α inhibition add the most value? Also watching #PAPMET2 in papillary RCC. @myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow